Sahm Adrangi is an influential hedge fudge manager who earned his BA of Arts and Economics from Yale University. In 2009 Sahm Adrangi founded Kerrisdale Capital Management LLC. His current active role within the company is Founder and Chief Investment Officer. He launched his company with under $1 million and as of July 2017 his firm manages over $150 Million.
Before Sahm Adrangi founded Kerrisdale Capital Management LLC he was an investment analyst at Longacre Fund Management LLC. Prior to becoming an investment analyst Sahm Adrangi helped people in and out of court with chapter 11 bankruptcy restructuring. Sahm Adrangi’s expertise in analyzing investment data helped him to predict two biotech failures in advance. One biotech failure that Sahm Adrangi was that Bavarian Nordic’s cancer vaccine would fail a study that would render it as nothing more than a placebo. Visit This Page to learn more.
Mr. Adrangi is also stating that another biotech company, Prothena, has manufactured a drug known as NEOD001 that will also be an absolute failure. After analyzing the potential of this drug, Kerrisdale Capital Management LLC has established that is has shown little promise in the phase I/II study. Sahm feels as though both of these drugs show no future in medical advancement and they are currently being traded as a penny stock. Mr. Adrangi is popularly known for short selling and publishing research. Kerrisdale’s research seeks to correct largely thought fallacies about business prospects.
Kerrisdale Capital management LLC shares their research not only on their company website but also on twitter and other investing sites. Sahm has appeared as a guest speaker for CNBS, Bloomberg and has been featured in articles by The Washington Post, Wall Street Journal and the New York Times. He is a known public speaker for investment events such as the Value Investing Conference, Sohn Conference and Traders 4 a Cause. His sound investment analysis has earned him a dedicated following seeking his knowledge and financial guidance.
Sahm Adrangi has initiated a short selling attack on the biotech company Prothena based on his research showing that their new drug for AL amyloidosis is ineffective. NEOD001 hasn’t completed Phase III testing yet, but Sahm Adrangi maintains that the results shown during Phase I and II were entirely coincidental and in no way related to the drug itself. AL amyloidosis causes the bone marrow to produce antibodies that effects the skin, liver, heart, and nerves. Investors reacted to this news and Prothena’s stock dropped by 8%.
The founder of Kerrisdale Capital Management LLC. and 2003 Yale University graduate has predicted the failure of drugs before, which is why investors are paying attention to Sahm Adrangi’s announcement. In 2017 he saw immense profits from the short selling of Bavarian Nordic and Sage Therapeutics after their prostate cancer vaccine and SRSE treatments were shown to be no more effective than placebo during final testing. Sahm Adrangi maintains that the early stage results were deliberately misrepresented to indicate much better outcomes than were actually produced.
Kerrisdale was founded in 2009 by Sahm Adrangi and now manages hundred millions of dollars. Adrangi, who acts as Chief Investment Officer at his company, raised around $100 million to fund just one attack against a single pharmaceutical company that was producing dishonest results on a drug in testing. Before founding Kerrisdale, Adrangi worked at Longacre Fund Management managing $2 billion in distressed debt as an analyst.
He has been featured in the Wall Street Journal, Washington Post, Business Week, and several other publications. The outspoken value investor releases the information he gathers about the companies he bets against through several different forms of media to ensure the public is aware of these companies’ business practices and don’t make bad investments. He often speaks at investment conferences, especially those focused on activism investing such as Traders 4 a Cause. Go To This Page for more information.
Along with biotech companies, he has expertise in mining and telecommunications as well. In 2014, he was granted a meeting with the Federal Communications Commission to discuss problems with Globalstar’s Terrestrial Low Power System after writing ex parte letters to the commission.
View Source: https://www.bloomberg.com/research/stocks/private/person.asp?personId=252047507&privcapId=109092301&previousCapId=109092301&previousTitle=Kerrisdale%20Capital%20Management%20LLC